Stockscreener 앱 받기
7.45
1.36%
0.10
시간 외 거래:
7.45
Grifols Sa Adr 주식(GRFS)의 최신 뉴스
SMRT’s latest rating updates from top analysts. - knoxdaily.com
Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com
Investing in Apellis Pharmaceuticals Inc (APLS) Is Getting More Attractive - knoxdaily.com
A company insider recently sold 10,000 shares of News Corp [NWSA]. Should You also Consider to Sale? - knoxdaily.com
Raymond James Downgrades Truist Financial Corporation (TFC) to a Mkt perform from an Outperform - knoxdaily.com
AT&T, Inc (T) rating upgrades by Exane BNP Paribas - knoxdaily.com
Grifols SA ADR (GRFS) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Lazard Inc (LAZ) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Can Verra Mobility Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
RYAN’s Market Whiplash: 0.32% YTD Rise, -10.03% Plunge in 30 Days - investchronicle.com
A significant driver of top-line growth: Grifols SA ADR (GRFS) - Sete News
SpringWorks Therapeutics Inc (SWTX) Stock: From Low to High in 52 Weeks - investchronicle.com
There is no doubt that Coeur Mining Inc (CDE) ticks all the boxes. - Sete News
GRFS (Grifols SA ADR) may reap gains as insiders became active recently - knoxdaily.com
BHP’s latest rating updates from top analysts. - knoxdaily.com
FHN’s latest rating updates from top analysts. - knoxdaily.com
Lake Street’s latest rating for ORGO stock - knoxdaily.com
Fox Corporation [FOX] stock was sold by MURDOCH KEITH RUPERT at the price of US$3.08 million - knoxdaily.com
6 undervalued stocks with low beta - Morningstar
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Barchart
BRF S.A. goes ex dividend tomorrow - MSN
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - MSN
Grifols falls amid potential Moody's downgrade, new short report - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Orange To Delist From NYSE To Reduce Financial Burdens - Yahoo Finance
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols, S.A. (BME:GRF) most popular amongst retail investors who own 45% of the shares, institutions hold 35% - Simply Wall St
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A.GRFS - PR Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
Grifols sees China stake sale going ahead despite Gotham City report - Reuters
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients - PR Newswire UK
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Novo Nordisk A/s Dividend History & Dividend Yield 2024 - INDmoney
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire
8 Newly Undervalued 5-Star Stocks - Morningstar
Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022 - PR Newswire
OZTA Stock Price and Chart — BER:OZTA - TradingView
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies - PR Newswire
How International Is Your Foreign-Stock Fund? - Morningstar
Estimating The Fair Value Of Grifols SA. (BME:GRF) - Yahoo Finance
GRF Stock Price and Chart — BME:GRF - TradingView
1.53%
자본화:
|
볼륨(24시간):